IRF3 and osteosarcoma: found that SGLT2 was overexpressed in osteosarcoma, and SGLT2i significantly inhibited osteosarcoma tumor growth and induced immune cell infiltration in vivo by up-regulating the expression of STING and activating the IRF3/IFN-β pathway (61).